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A B S T R A C T
Background
Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus
in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen,
and sulfated proteoglycans. Mutations or deletions involving a3(IV), a4(IV), or a5(IV) chains of
type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans,
a progressive hereditary kidney disease associated with deafness. The pathological mechanisms
by which such mutations lead to eventual kidney failure are not completely understood.
Methods and Findings
We showed that increased susceptibility of defective human Alport GBM to proteolytic
degradation is mediated by three different matrix metalloproteinases (MMPs)—MMP-2, MMP-3,
and MMP-9—which influence the progression of renal dysfunction in a3(IV)/ mice, a model
for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and
MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus.
Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs,
before the onset of proteinuria or GBM structural defects in the a3(IV)/mice, led to significant
attenuation in disease progression associated with delayed proteinuria and marked extension
in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of
disease associated with extensive interstitial fibrosis and early death of a3(IV)/ mice.
Conclusions
These results suggest that preserving GBM/extracellular matrix integrity before the onset of
proteinuria leads to significant disease protection, but if this window of opportunity is lost,
MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and
interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport
disease in a3(IV)/mice, with an early pathogenic function and a later protective action. Hence,
we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport
syndrome with identified genetic defects, before the onset of proteinuria.
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Introduction
Basement membranes (BMs) are dynamic structures which
provide structural support and contribute to the acquisition
of cellular phenotype and functional behavior [1,2]. Major
constituents of all BMs are predominantly laminins, nidogen/
entactin, heparan sulfate proteoglycans, and type IV colla-
gens—and the latter, as the most abundant BM-associated
protein, also serves as a scaffold on which other BM proteins
may interact [1–3]. Type IV collagen includes six genetically
distinct isoforms named a1(IV) to a6(IV) [1]. The six different
isoforms are differentially expressed in various BMs and
assembled into distinct networks, which potentially provide
BM tissue–specificity [4]. While a1(IV) and a2(IV) chains are
the most abundant isoforms in most BMs, distinct isoform
compositions involving a3(IV)–a6(IV) are considered to
represent specialized adaptation of BMs to site-specific
requirements [1].
Mutations in type IV collagen have been linked to the
genetic disorder Alport syndrome [5–7]. Classically, Alport
syndrome constitutes progressive renal disease associated
with sensorineural deafness and occasional ocular defects
[8,9]. The renal disease associated with Alport syndrome
causes hematuria, proteinuria, and progressive renal failure
[9,10]. The typical histopathological correlate of Alport
disease in the kidney is splitting, thinning, and thickening
of the glomerular basement membrane (GBM), which
coincides with the onset of hematuria and proteinuria [11].
Several genetic studies have revealed that Alport syndrome
is caused by mutations in the genes encoding for a3(IV),
a4(IV), and a5(IV) chains of type IV collagen [9]. Mutations in
the gene on chromosome X,q26–q48, which encodes for the
COL4A5 chain, result in the X-linked form of Alport
syndrome, accounting for approximately 85% of patients
with Alport syndrome [7,9,]. Mutations in the COL4A3 or
COL4A4 genes, which encode for the a3(IV) and a4(IV) chains,
cause autosomal recessive forms of this disease or, in rare
occasions, autosomal dominant inherited forms of this
disease [9,12,13].
Pathological mechanisms by which mutations in the
COL4A3/COL4A4/COL4A5 genes translate into renal disease
are not fully understood [9]. The a3(IV), a4(IV), and a5(IV)
chains of type IV collagen assemble into a unique network in
the GBM, which is a central constituent of the filtration
apparatus in the kidney. During kidney development, fetal
a1(IV) and a2(IV) chain networks of the early GBM are
replaced by the adult a3(IV), a4(IV), and a5(IV) chain
networks in the mature GBM, and this isoform switching is
arrested in patients with Alport syndrome, owing to defective
assembly involving mutated type IV collagen genes [14]. In
most patients with the X-linked form of Alport syndrome, the
a3(IV), a4(IV), and a5(IV) chains are undetectable in the
kidneys, suggesting that these three chains depend on each
other for their incorporation into the GBM [9,15].
As a major component of the ultra-filtration apparatus in
the kidney, GBM, unlike any other BM, is constantly exposed
to serum flow/pressure and thus needs to be functionally
sound and needs to stringently maintain its structural
integrity. It was previously proposed that a1(IV) and a2(IV)
chain networks are less resistant to physical forces associated
with constant filtration and exposure to endogenous local
proteases when compared to more cross-linked a3(IV), a4(IV),
and a5(IV) networks [9,14]. Previous studies suggested that
abnormal persistence of a1(IV) and a2(IV) isoforms in the
Alport GBM is associated with an increased susceptibility to
proteolysis by proteases [14]. However, studies utilizing mice
that are deficient in both the a3(IV) chain of type IV collagen
and matrix metalloproteinase (MMP)–9 failed to provide
evidence for the role of MMP-9 in the initiation and
progression of renal disease [16]. Here, we hypothesized that
MMPs with overlapping substrate specificities could compen-
sate for each other’s absence in the setting of GBM-
degradation, and we aimed to evaluate the impact of type
IV collagen-degrading proteases on the progression of kidney
disease associated with Alport syndrome using combined
pharmacological inhibition of MMPs.
Methods
Mice
MMP-2/, MMP-3/, MMP-9/, and a3(IV)/ mice on a
C57/BL6 background were generated as described previously
[17–20]. Double-mutant (MMP-2/; MMP-9/) mice were
generated by crossbreeding MMP-2/ and MMP-9/ mice.
Mouse studies followed the Institutional Animal Care and Use
Guidelines. Age-matched mice were used for all studies.
Human Samples
Nonfunctioning X-linked Alport syndrome (XAS) kidneys
were obtained from two different male patients with XAS, in
whom it was deemed appropriate to remove the diseased
kidney at the time of transplant surgery. Kidneys from a 28-y-
old patient with XAS (serum creatinine 459.7 lmol/l; patient
XAS1) and a 42-y-old male patient with XAS (serum
creatinine 1,582.4 lmol/l; patient XAS2) were used for
immunostaining and immunoblot analysis for MMP expres-
sion. Normal human kidney tissue was obtained from a
kidney that was not used for transplantation, and from
histologically normal portions of resected kidneys with renal
cell carcinoma. All specimen samples were provided by C.
Shield III under appropriate patient consent and institu-
tional approval.
Preparation of Renal Basement Membranes
Renal basement membranes (RBMs) from mouse and
human kidneys were isolated as described previously, with
minor modifications [14,21]. Mouse kidneys were obtained
from 8-wk-old a3(IV)/mice and from age-matched C57BL/6
control mice. Human RBM was obtained from nonfunction-
ing kidneys from male patients with confirmed XAS (from the
patients described above) and from normal kidneys not used
for transplantation [14,22]. Kidney cortexes were shaved into
an ice-cold solution of 0.85% NaCl containing protease-
inhibitors (di-isopropylfluorophosphate [DFP], N-ethylmalei-
mide [NEM], e-aminocaproate, and EDTA). The shavings were
passed through a meat grinder and diluted with the above
solution. The solution was suspended in 2% deoxycholate and
stirred for 4 h at room temperature. The suspension was
centrifuged, washed three times with ice-cold distilled water,
and frozen at 20 8C immediately.
Degradation of RBM by MMPs
RBM (500 lg) prepared from either control C57BL/6 mice,
a3(IV)/ mice, normal human kidneys, or kidneys obtained
from patients with XAS were suspended in 500 ll of 50 mM
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Tris-HCl, (pH 7.5), containing 1 mM calcium chloride and
0.02 % sodium azide as described previously [14,21].
Recombinant active MMP-9, MMP-2, or MMP-3 (Calbiochem,
San Diego, California, United States) was added at an enzyme-
to-substrate ratio of 1:500, and digestion was continued at 37
8C. The reaction was stopped by addition of 50 ll of 150 mM
EDTA, and the samples were frozen at 20 8C until analysis.
The amount of type IV collagen degradation was quantified
by measuring hydroxyproline released into the digestion
supernatant as previously described [14,21].
Western Blot Analysis
Total protein was extracted from renal cortex using the T-
PER Tissue Protein Extraction Reagent according to the
manufacturer’s recommendations (Pierce Biotechnology,
Rockford, Illinois, United States). Protein concentration was
assessed using the BCA protein assay (Pierce Biotechnology).
For SDS PAGE, 200 lg of protein was loaded into each well.
For Western blot analysis, proteins were transferred to Trans-
Blot nitrocellulose membranes (Bio-Rad, Hercules, Califor-
nia, United States) and then probed with antibodies to MMP-
2 (1:1,000, Calbiochem), MMP-3 (1:3000, Chemicon [http://
www.chemicon.com]), MMP-9 (1:1000, Chemicon), and HRP-
conjugated secondary antibodies for 1 h each at room
temperature. After extensive washes, bands were visualized
using reagents for enhanced chemiluminescence (ECL West-
ern blotting kit, Amersham Biosciences, Little Chalfont,
United Kingdom). For confirmation of equal loading, the
blots were stripped and reprobed with antibodies to actin as
described previously. The band corresponding to hexamers
was cut out and protein was extracted.
Immunohistochemistry
Immunohistochemical staining and electron microscopy
was performed as previously described [23]. We used
commercially available polyclonal antibodies to recognize
MMP-2 (Calbiochem), MMP-3 (Chemicon), MMP-9 (Chem-
icon), and entactin/nidogen-1 (Sigma, St. Louis, Missouri,
United States) in mice. For the detection of MMPs in human
tissue sections, we used commercially available mouse
monoclonal antibodies to MMP-2 (Calbiochem), MMP-3
(Calbiochem), MMP-9 (Calbiochem), and type IV collagen
(Southern Biotechnologies, Birmingham, Alabama, United
States). Briefly, 4-lm cryostat sections were fixed in 100%
acetone at 20 8C for 10 min. The sections were incubated
with primary antibodies at 4 8C overnight. Subsequently, the
slides were washed three times in Tris-buffered saline (TBS)
and incubated with donkey-derived secondary antibodies
conjugated with Rhodamine or FITC (Jackson Immunore-
search, West Grove, Pennsylvania, United States). After four
washes with TBS, the slides were mounted with Vectashield
mounting media (Vector Laboratories, www.vectorlabs.com)
and cover-slipped. The staining was analyzed using a
fluorescence microscope (Zeiss Axioskop 2plus, http://www.
zeiss.com) and visualized using Zeiss Axiovision digital
imaging software. Areas of MMP-staining in the glomeruli
and total cortex were quantified using NIH ImageJ software
(http://www.nih.gov). To assess glomerular staining, 20 glo-
meruli in randomly picked visual fields were assessed. To
determine MMP-staining in the kidney cortex, visual fields at
a magnification of 3200 were assessed in five mouse-kidney
samples and ten human-kidney samples.
In Situ Zymography
In situ zymography was performed as described previously
[24,25], but with some modifications. Briefly, the frozen
blocks were sectioned sequentially using a cryostat micro-
tome to prepare serial frozen thin sections (5 lm thickness).
These thin sections were placed on a FIZ film (Fuji Photo
Film, Tokyo, Japan). The films with sections were incubated
for 12 h at 37 8C in a humidified chamber and stained with
1% Amido Black 10B in 40% methyl alcohol, 10% acetic acid,
and 10% glycerol for10 min, destained in 40% methyl
alcohol, 10% acetic acid, and 10% glycerol for 20 min, and
kept in 20% glycerol for another 20 min. The sections were
cover-slipped, sealed, and imaged using an Olympus BH-2
(http://www.olympusmicro.com) microscope interfaced with a
Spot-RT digital camera (Olympus). The gelatin in contact
with the proteolytic areas of the section is digested, revealing
white-to-pale blue areas on the otherwise black background.
To confirm the specificity of in situ zymography, frozen
sections were also placed on gelatin-coated films containing
1,10-phenanthroline (GI films), which is known to inhibit the
activity of MMPs (unpublished data). In order to test the
efficacy of the MMP-inhibitor cocktail, we employed the same
MMP-inhibitors used for the in vivo studies at concentrations
aimed to approximate sustained serum concentrations
expected at the doses administered. MMP-2/MMP-9–inhibitor
(2R)-[(4-biphenylsulfonyl)amino]-N-hydroxy-3-phenylpropio-
natamide and MMP-3–inhibitor N-isobutyl-N-(4-methoxyl-
phenylsulfonyl)-glycylhydroxamic acid (Calbiochem) were
used. The films were first immersed in the inhibitors (MMP-
2/MMP-9–inhibitor at 800 nM and MMP-3–inhibitor at 300
nM), which were dissolved in saline (0.9% NaCl) at 300 lM for
10 min. The films were then thoroughly dried at room
temperature and were used for inhibition studies [26].
In Vivo Inhibition of MMPs
MMP-2, MMP-3, and MMP-9 were inhibited in a3(IV)/
mice starting after 4 wk and after 8 wk of age (n ¼ 6 mice in
each group); control a3(IV)/ mice (n ¼ 6) received control
buffer. Serum samples were obtained weekly, and urine
samples were collected using metabolic cages once a week.
MMP-2/MMP-9–inhibitor (2R)-[(4-biphenylsulfonyl)amino]-N-
hydroxy-3-phenylpropionamide (Calbiochem) and MMP-3–
inhibitor N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycylhy-
droxamic acid (Calbiochem) were administered orally as
described previously [27–29]. MMP-2/MMP-9–inhibitor was
suspended in vehicle buffer (saline including 0.4% Tween 80,
0.5% carboxymethylcellulose, and 0.9% benzyl alcohol)
administered daily at a dose of 200 mg/kg po, which has been
demonstrated to inhibit MMP-2 and MMP-9 in mice [28,29].
MMP-3–inhibitor was administered at a dose of 75 lmol/kg
dissolved in cornstarch [27]. Control mice were administered
vehicle buffers alone.
Statistical Analysis
All values are expressed as mean 6 standard error of the
mean unless specified. Analysis of variance (ANOVA) was
used to determine statistical differences between groups
using Sigma-Stat software (Jandel Scientific, San Rafael,
California, United States). Further analysis was carried out
using Students t-test with Bonferroni correction to identify
significant differences. A level of p , 0.05 was considered
statistically significant.
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Figure 1. MMP Expression in Kidneys of a3(IV)/ Mutant and Wild-Type Mice
Frozen sections of control C57/Bl6 mice and a3(IV)/ mice were stained with primary antibodies for MMP-2, MMP-3, and MMP-9 (FITC-green), and
sections were counterstained with Rhodamine-labeled antibodies for entactin (red).
(A) In control C57/Bl6 mice, MMP-2 is present sporadically in the glomeruli and in some proximal tubules (arrows).
(B) After 4 wk of age, MMP-2 is increased in the glomeruli (arrows) in a3(IV)/ mice compared to age-matched control kidneys, even before
manifestation of proteinuria.
(C) After 8 wk of age (after manifestation of GBM-splitting and initiation of interstitial fibrosis), MMP-2 is increased in the interstitium (arrowheads) and
in the glomeruli (arrows) in kidneys from a3(IV)/ mice.
(D) MMP-2–staining was quantified using NIH ImageJ software in the glomeruli (left panels) and in total kidney cortex. Glomerular MMP-2–staining was
significantly increased at 4 wk in a3(IV)/ as compared with control. ***p , 0.001 versus control.
(E) MMP-2 expression was analyzed by immunoblot using total protein from the kidney cortex of single mice. A representative blot is shown, confirming
increased expression of MMP-2 in a3(IV)/. The lower blot displays the control blot for actin to confirm equal loading.
(F) Immunofluorescence staining revealed that MMP-3–staining is present in the glomeruli (arrows) of control C57/Bl6 mice.
(G) MMP-3 is significantly increased in the glomeruli of a3(IV)/ mice after 4 wk of age.
(H) In 8-wk-old a3(IV)/ mice, MMP-3 is up-regulated in the interstitium (arrowheads) and MMP-3 is also present in the glomeruli (arrows).
(I) Quantification of MMP-3–staining revealed a significant increase of MMP-3–staining in the glomeruli and total cortex of a3(IV)/mice at 4 wk and 8
wk of age. ***p , 0.001 versus control.
(J) Immunoblot analysis revealed increased renal MMP-3 protein.
(K) MMP-9 is present in the glomeruli of C57/Bl6 control mice (arrows).
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Results
MMP Localization during Progression of Renal Disease in
a3(IV)/ Mice
The a3(IV)/ mice used in this study have a normal
phenotype until 4–6 wk of age [30–32]. Before 5 wk, the
GBM contains minimal structural damage and the overall
histology is healthy [33]. Additionally, it is important to stress
that before week 5, no pathologic alterations in the
tubulointerstitial compartment of the kidney can be detected
[18,31,33]. After 4–5 wk post-partum, proteinuria and
splitting of GBM is initiated [31,33]. At 8 wk of age, severe
splitting and thinning of the GBM are observed, associated
with podocyte effacement and significant increase in urine
protein levels, indicating malfunction of the glomerular
filtration barrier [31,33] At this stage, tubulointerstitial
fibrosis, a common destructive pathway for many chronic
nephropathies, is observed [30,31].
We evaluated the expression of glomerular MMP-2, MMP-3,
and MMP-9 in the context of glomerular diseases in the
a3(IV) collagen-deficient mice. The analysis was performed at
4 wk of age when minimal splitting of GBM occurs (preceding
podocyte effacement and proteinuria), and after 8 wk of age
(when glomerular kidney disease is robust and progresses
towards tubulointerstitial fibrosis). In normal wild-type mice,
low baseline levels of MMP-2 were detected within the
glomeruli, while it was absent within the tubulointerstitium
(Figure 1A). At week 4, before the onset of proteinuria in the
a3(IV)/ mice, we detected significant glomerular expression
of MMP-2, and this expression spread to the tubulointerstitial
compartment when the mice exhibited proteinuria at 8 wk
(Figure 1B and 1C). Quantification of MMP-2–staining using
NIH ImageJ software revealed a significant increase of
glomerular MMP-2–staining at 4 wk of age in a3(IV)/ mice
compared with control C57/BL6 mice (Figure 1D). Increase of
MMP-2–staining within the tubulointerstitial compartment
was reflected by a significant increase in MMP-2–staining
when the entire cortex region was analyzed (Figure 1D).
Presence of low levels of MMP-2 within the kidney cortex and
increased MMP-2–expression in a3(IV)/ mice at 4 wk and 8
wk of age was confirmed by immunoblot using total protein
lysates isolated from kidney cortex (Figure 1E). Low levels of
MMP-3 were present in the glomeruli of C57/BL6 control
mice (Figure 1F), but MMP-3 levels were significantly up-
regulated in the week-4 a3(IV)/ glomeruli (Figure 1F–1I). At
8 wk in the a3(IV)/ mice, MMP-3 expression spread
predominantly to the tubulointerstitial compartment (Figure
1H–1J). MMP-9 was observed predominantly in the tubules of
normal mice (Figure 1K); by 4 wk in the a3(IV)/ mice, low-
level expression was observed in the glomeruli, which shifted
into the interstitial space at 8 wk of age in the mutant mice
(Figure 1L–1O). These results demonstrate that spreading of
the disease from the glomeruli into the tubulointerstitial
compartment is associated with MMP re-localization.
Increased Renal Expression of MMP-2, MMP-3, and MMP-9
in the Kidney of Patients with XAS
In order to assess the relevance of our findings of increased
MMP expression in kidneys of a3(IV)/ mice with respect to
human disease, we evaluated the expression of MMP-2, MMP-
3, and MMP-9 in normal human kidneys and in kidneys
obtained from patients with XAS. Whereas low levels of MMP-
2, MMP-3, andMMP-9 could be detected by immufluorescence
staining and immunoblotting in normal kidney tissue (Figure
2A–2C), MMP-2, MMP-3, and MMP-9 levels were significantly
increased in kidneys obtained from patients with end-stage
renal failure owing to XAS (Figure 2D–2L).
Degradation of RBM by MMP-2, MMP-3, and MMP-9
MMP-2, MMP-3, and MMP-9—important BM-degrading
enzymes—are found circulating in the blood of normal mice
and humans [34–36]. Here we investigated whether MMP-2,
MMP-3, and MMP-9 were all capable of degrading human and
mouse BM preparations (RBM, measured by hydroxyproline
release as a function of time). MMP-dependent degradation
was significantly enhanced when Alport RBMs or RBMs from
a3(IV)-deficient mice were used (Figure 3A and 3B). Without
digestion, the hydroxyproline release did not increase over
time, indicating that it was the type IV collagen composition,
and not unspecific degradation of diseased GBM isolated
from diseased kidneys, that accounted for this effect. These
experiments suggest that MMPs present in the altered
glomerular microenvironment are capable of degrading the
Alport GBM much faster than the normal GBM.
Compensatory Over-Expression of BM-Degrading MMPs in
Mice Deficient in MMP-2, MMP-3, and MMP-9, or Deficient
in MMP-2 and MMP-9 Only
Our studies point to the fact that enhanced degradation of
GBM by BM-degrading MMPs could represent a crucial step
in the renal disease progression observed in human Alport
syndrome and also in the a3(IV)/mice (see above). However,
a recent study with mice deficient in both MMP-9 and a3(IV)
collagen suggested that ablation of MMP-9 does not alter
renal disease progression in the a3(IV)/ mice [16]. We
hypothesized that this observation could be due to compen-
satory over-expression of other BM-degrading MMPs when
one of them is deleted. To test this hypothesis, we performed
immunostaining experiments for BM-degrading MMPs in
mice deficient in one or more MMPs.
Mice that are deficient in MMP-2 (MMP-2/), MMP-3
(MMP-3/), and MMP-9 (MMP-9/), or which are deficient in
MMP-2 and MMP-9 (MMP-2/; MMP-9/) only, are viable and
do not display significant phenotypic abnormalities in the
kidney [17,19]. In the normal mice, MMP-2 and MMP-9, and
to a lesser extent MMP-3, were detected in the glomeruli
(Figure 4A–4C). In MMP-2/ mice, compensatory up-regu-
lation of MMP-3 and MMP-9 was observed in the glomeruli
(Figure 4D–4F). In MMP-9/mice, the absence of basal MMP-
(L) The onset of proteinuria is preceded by a significant increase of MMP-9 in the glomeruli of a3(IV)/ mice (arrows).
(M) MMP-9 is significantly up-regulated in the interstitium (arrowheads) and in the glomeruli (arrows) of 8-wk-old a3(IV)/mice compared to control.
(N) Quantification of immunofluorescence staining using ImageJ software confirmed a significant increase of MMP-9 expression in the glomeruli (left
panels) and total cortex region (right panels) of a3(IV)/mice as compared with control. ***p , 0.001 versus control.
(O) Increased MMP-9 expression was confirmed by immunoblot.
DOI: 10.1371/journal.pmed.0030100.g001
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9 expression was counterbalanced by a robust increase in
MMP-2 and MMP-3 (Figure 4G–4I). In the double-mutant
(MMP-2/; MMP-9/) mice, MMP-3 expression was dramat-
ically up-regulated (Figure 4J–4L), whereas in MMP-3/mice,
compensatory increase of MMP-2– and MMP-9–staining was
documented as compared with C57BL/6 control mice (Figure
4M–4O). These findings were also confirmed by immunoblot
analysis of total protein lysates isolated from the kidney
cortex. Immunoblot analysis revealed compensatory up-
regulation of other MMPs when MMP-2 and/or MMP-9 were
deleted in mice (Figure 4P–4R). Such compensatory increase
of MMPs with overlapping substrate-specificities has been
demonstrated before in the uterus of matrilysin-deficient
mice, where the absence of matrilysin was counterbalanced
by increased MMP-3 expression, and in MMP-3/, mice in
which the absence of MMP-3 (stromelysin-1) was associated
with increased expression of MMP-10 (stromelysin-2) as well
as of MMP-11 (stromelysin-3) [37]. These findings suggest that
deletion of one MMP is not sufficient to halt the progression
of renal disease associated with a3(IV)/ mice, owing to
compensatory up-regulation of other BM-degrading MMPs.
Combined Pharmacological Inhibition of MMP-2, MMP-3,
and MMP-9 Activity in a3(IV)/ Mice
To evaluate the combined roles of MMP-2, MMP-3, and
MMP-9 in the progression of renal disease in a3(IV)/ mice,
Figure 2. MMP Expression in Kidneys of Patients with XAS and in Normal Human Kidneys
(A–F) Frozen sections of normal human kidneys and kidneys from patients with ESRD due to XAS were stained with antibodies to MMP-2, MMP-3, and
MMP-9 (FITC-green), plus laminin (Rhodamine red). Representative stainings of samples obtained from a kidney designated for transplantation or from
normal portions of resected kidneys with renal cell carcinoma are displayed. (A–C) Control. (D–F) Kidneys (n¼ 2) obtained from male patients with XAS.
(G–I) The bar graphs summarize the quantification of MMP-2–staining (G), MMP-3–staining (H), and MMP-9–staining (I). The left bars summarize the
evaluation of MMP-staining in the glomeruli; the right bars summarize the MMP-staining in the total kidney cortex in each panel. ***p , 0.001 versus
control; **p , 0.005 versus control; *p , 0.01 versus control.
(J–L) Total protein was isolated from normal human kidneys and from two kidneys obtained from two different patients with ESRD due to XAS. Protein
was analyzed by SDS-PAGE and immunoblot using specific antibodies to MMP-2 (J), MMP-3 (K), and MMP-9 (L). The lower blots in each panel display the
actin control blot to control for equal protein loading.
DOI: 10.1371/journal.pmed.0030100.g002
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we treated a3(IV)/ mice with a combination of MMP-
inhibitors to block MMP-2, MMP-3, and MMP-9 at the same
time [27,28]. We used a combination of the MMP-2/MMP-9–
inhibitor (2R)-[(4-biphenylsulfonyl)amino]-N-hydroxy-3-phe-
nylpropionamide and the MMP-3–inhibitor N-isobutyl-N-(4-
methoxyphenylsulfonyl)-glycylhydroxamic acid, which were
administered orally as a combination-drug cocktail to normal
mice, 5-wk-old a3(IV)/ mice, and 8-wk-old a3(IV)/ mice
[29,38]. We used in situ zymography to verify that MMP
activity was increased in a3(IV)/ mice and that these MMPs
were inhibited by the MMP-inhibitor cocktail (Figure 5). Our
findings do not exclude the possibility that additional MMPs
with gelatin-degrading capacity were also inhibited, which
would be a desired effect, as our goal was to evaluate the
overall effect of BM-degrading MMPs in this disease model as
opposed to delineating specific roles of single MMPs.
The progression of kidney disease in a3(IV)/ mice is
consistent, resulting in end-stage renal failure after 14 wk of
age. At the age of 3 and 4 wk, the mice present a normal kidney
morphology (Figure 5G and 5H). After 4–5 wk of age,
disruption of theGBM results in proteinuria, which is reflected
by tubules filled with protein casts after 6 wk of age (Figure 5I).
At the age of 8 wk, the kidney is marked by the onset of more
severe tubulointerstitial disease, associated with tubular injury
and interstitial infiltration with mononuclear cells (Figure 5J).
After 10 wk, the kidneys present with vast areas with interstitial
inflammation (Figure 5K), which results in severe fibrosis and
end-stage renal failure after 14 wk (Figure 5L). Initiation of
MMP-inhibition, starting after 4 wk of age (before the onset of
significant GBM damage and proteinuria) for 9 wk, dramati-
cally delayed progression of renal disease in a3(IV)/mice. At
week 14, when end-stage renal disease (ESRD) was evident in
untreated a3(IV)/ mice, the treated mice exhibited almost
normal levels of serum creatinine and urine protein (Figure 5E
and 5F). We also observed significant improvement in renal
histology compared to untreated mice (Figure 5M, compare
with Figure 5L). While the untreated Alport mice died at
around 14 wk, the treated mice lived for an additional 5 wk,
demonstrating significant extension of survival upon MMP-
inhibition treatment.
In contrast, inhibition of MMPs starting at 8 wk of age,
(after the onset of proteinuria and the emergence of
interstitial fibrosis (Figure 5J) for 4 wk, led to significant
enhancement in disease progression with most mice dying
between week 10 and week 12 (Figure 5N, compare with
Figure 5K). Serum creatinine levels and urine protein
excretion was significantly enhanced after the start of
MMP-inhibition, and renal disease rapidly progressed to-
wards death by 11–12 wk of age, as compared with 14–15 wk
in control untreated a3(IV)/ mice (Figure 5E and 5F). This
acceleration of disease was associated with significant
increase in both glomerular and interstitial fibrosis.
Ultrastructural Analysis of GBM in MMP-Inhibitor–Treated
Mice
We used transmission electron microscopy to analyze the
architecture of the GBM before and after treatment with
MMP-inhibitors. Normal mice at 5 wk of age and 14 wk of age
showed normal GBM structure (unpublished data; Figure 6A).
Five-week-old a3(IV)/ mice treated for 9 wk with MMP-
inhibitors exhibited significant protection of GBM architec-
ture when compared to age-matched untreated mice with
ESRD (14 wk) (Figure 6B–6D).
Figure 3. Increased Susceptibility to Proteolytic Degradation by MMPs of RBM from Patients with XAS and a3(IV)/ Mice
(A) Degradation of human RBM by MMP-2, MMP-3, and MMP-9. RBM was isolated from human control kidneys and from patients with XAS. RBM was
incubated with MMPs, and proteolysis was assessed by estimation of hydroxyproline release. The graph displays the relative increase of hydroxyproline
over time. Experiments using normal RBM are represented by dotted lines; studies with RBM from patients with XAS are represented by a full line.
Hydroxyproline release after MMP-2 incubation is displayed by black lines, MMP-3 incubation by green lines, and MMP-9 incubation by red lines.
Proteolysis of Alport BM was significantly enhanced compared with normal human RBM by each of these MMPS.
(B) Degradation of mouse RBM by MMP-2, MMP-3, and MMP-9. RBM was collected from normal C57BL/6 mice (n¼6) and from a3(IV)/mice (n¼6) and
subjected to active MMPs. Experiments using normal RBM are represented by dotted lines; studies with RBM from a3(IV)/mice are represented by a
full line. Hydroxyproline release after MMP-2 incubation is displayed by black lines, MMP-3 incubation by green lines, and MMP-9 incubation by red
lines. Similarly to human Alport RBM, the RBM from a3(IV)/ mice displayed an increased susceptibility to proteolysis by MMPs.
DOI: 10.1371/journal.pmed.0030100.g003
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Discussion
In the present study, we demonstrate that in a3(IV)/mice,
a mouse model for human Alport syndrome, BMs and
extracellular matrix (ECM)–degrading MMPs exhibit distinct
functions in early and in late stages of disease progression.
Additionally, we demonstrate the utility of MMP-inhibitors
for significant attenuation of Alport renal disease, when
administered at an early phase.
Interestingly, this discovery reminds us of recently pub-
lished reports in the area of cancer research, where MMPs, in
particular MMP-9, are identified as possessing an early pro-
cancer property and a late anti-cancer activity [39,40].
Therefore our results add to the growing body of literature
that MMPs can exhibit context-dependent, contrasting func-
tions. Thus it is vital to undertake a mechanistic evaluation of
the means by which MMPs regulate disease progression before
they can be considered as therapeutic targets.
The concept for the pathogenesis of Alport syndrome is
that mutations in any of three chains of type IV collagen (a3,
a4, and a5) lead to defective GBM. In the present study, we
demonstrate that MMP-2, MMP-3, and MMP-9 are present in
the glomeruli of normal adult mice at low, yet constant,
physiological levels, confirming previous observations [41–
43]. However, the normal type IV collagen and laminin
composition of the GBM appears sufficient to prevent
accelerated deterioration of the glomerular filtration barrier
despite the constant presence of MMPs. The possible
importance of increased MMPs in the degradation of even
normal GBM is demonstrated in studies in which increased
levels of reactive oxygen species led to potentially enhanced
activation of MMPs and deterioration of the glomerular
filtration barrier [22,44]. In this regard, pretreatment of rat
GBM with H2O2 increases its susceptibility to degradation by
proteases [44], and reactive oxygen species by themselves can
increase the expression of MMPs in glomerular epithelial cells
[45]. The importance of such exposure of the kidney GBM to
MMPs and physical stress is further corroborated by the fact
that in patients with XAS, the alveolar basement membrane
in the lung—which normally contains the a3(IV), a4(IV), and
a5(IV) chains of type IV collagen—remains normal in the
functional sense [30].
In a3(IV)/ mice, the abnormal GBM composition is more
susceptible to proteolytic degradation compared with wild-
type mice, and the initial disruption of GBM is associated
with further increased MMP levels from infiltrating mono-
cytes, further augmenting GBM-degradation in these mice
[25]. Combined inhibition of BM-degrading MMPs signifi-
cantly delayed the onset of proteinuria in these mice when
they were treated before proteinuria was observed. Similarly,
we demonstrated that RBM isolated from human kidney
samples with XAS displays an increased susceptibility to
proteolytic degradation by MMP-2, MMP-3, and MMP-9, and
that the progression of renal disease in patients with XAS is
associated with increased expression of MMP-2, MMP-3, and
MMP-9 as in the a3(IV)/ mice. These results suggest that
MMP-mediated degradation of GBM is a key event in the
progression of renal disease in a3(IV)/mice and in patients
with XAS. Such MMP up-regulation is not unique to Alport
disease only. However, in the context of Alport disease, such
MMP up-regulation degrades the GBM faster owing to
defective type IV collagen composition, whereas the degra-
dation kinetics are unaltered in other kidney diseases. While
our results suggest that MMP-2, MMP-3, and MMP-9 are the
Figure 4. Compensation of BM-Degrading MMPs in MMP-2/, MMP-3/, and MMP-9/ Mice, and in MMP-2/ and MMP-9/ Mice
Immunohistochemical staining was performed with MMP-2, MMP-3, or MMP-9–antibodies (green) and with antibodies for entactin (red) on frozen kidney
sections from MMP-2/ and MMP-9/mice, and from MMP-2/ and MMP-9/mice plus C57Bl/6 age-matched control mice.
(A–C) Wild-type control kidney. Immunohistochemical staining demonstrated basal expression of MMP-2, MMP-3, or MMP-9 in the glomeruli of C57BL/6
mice.
(D–F) MMP-2/ kidney. In MMP-2/ mice, the absence of MMP-2 was associated with a compensatory increase of MMP-3 and MMP-9.
(G–I) MMP-9/ kidney. MMP-9–deficiency was associated with increased MMP-2– and MMP-3–staining.
(J–L) MMP-2/ and MMP-9/ kidney. The absence of both MMP-2 and MMP-9 was associated with a substantial increase of MMP-3 in the glomeruli of
MMP-2/ or MMP-9/ double-mutant mice.
(M–O) MMP-3/ kidney. In MMP-3/ mice, the absence of MMP-3 was associated with increased glomerular staining for MMP-2 and MMP-9.
(P–R) Immunoblot analysis. Immunoblot analysis of total kidney-cortex protein preparations with antibodies specific for MMP-2 (M), MMP-3 (N), and
MMP-9 (O) confirmed compensatory up-regulation of MMPs. The blots were stripped and reprobed with antibodies to actin in order to confirm equal
loading (lower panels).
DOI: 10.1371/journal.pmed.0030100.g004
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Figure 5. Effect of Combined MMP-Inhibition on the Progression of Renal Disease in a3(IV)/ Mice
(A–D) In situ zymography. In situ zymography displayed gelatin-degrading activity in normal kidneys (A), which was substantially increased in kidneys of
14-wk-old COL4A3/ mice (B). Incubation with the MMP-2, MMP-3, or MMP-9–inhibitor cocktail significantly blocked MMP activities in kidneys from
wild-type mice (C) and kidneys from COL4A3/ mice (D).
(E and F) Renal function in a3(IV)/ mice. Urinary protein excretion (E) was measured in urine, which was collected over a 24-h period in metabolic
cages. Serum creatinine (F) was determined in serum samples that were obtained bi-weekly from mice. The graphs display the progression of urinary
protein excretion and serum creatinine levels from 4 to 14 wk of age. In each panel, disease progression is shown in untreated control mice (black), in
mice that received MMP-inhibitors starting at 5 wk of age (red), and in mice that received MMP-inhibitors starting at 8 wk of age (green).
(G–N) Kidney histology from a3(IV)/ mice. The images display representative periodic acid-Schiff (PAS)–stained kidney sections from a3(IV)/ mice,
togetherwith images displaying representative kidneys fromuntreateda3(IV)/mice to illustrate disease progression (G–L). At the ageof 3wk, the kidneys
appear completely normal (G). At 4wkof age, a fewglomeruli appearhypercellular, representativeof inflammatory cells (H). At the ageof 6wk, a few tubules
filled with protein casts appear (I). At 8 wk of age, a few sclerotic glomeruli are present, and atrophic tubules containing protein casts become more
abundant (J). At the age of 10wk, increased numbers ofmononuclear cells associatedwithwidening of the interstitial space indicate the onset of interstitial
fibrosis (K). At 14 wk of age, the kidneys display severe tubular atrophy, glomerulosclerosis, and interstitial fibrosis, reflecting ESRD (L). A kidney section is
displayed of a 14-wk-old a3(IV)/mouse that received MMP-inhibitors from 4 wk of age (M). Initiation of treatment after week 4 (compare with H) led to
substantially ameliorated disease after 14 wk (M, compare with L). A representative kidney section of a a3(IV)/mice at week 11 that received MMP-2–
inhibitors, MMP-9–inhibitors, and MMP-3–inhibitors, starting at week 8 and displaying enhanced progression of disease, is displayed (N, compare with K).
(Original magnification of PAS-stained histologies:3200).
(O and P) Representative kidney sections from wild-type control mice at 4 wk of age (O) and 14 wk of age (P) are displayed. (Original magnification of
PAS-stained histologies:3200).
DOI: 10.1371/journal.pmed.0030100.g005
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principal MMPs involved in this process, we cannot exclude
the possibility that other BM-degrading MMPs are also likely
involved. In contrast, after the onset of proteinuria and
accumulation of significant damage to the GBM, the renal
disease in these mice is no longer dependent on MMP activity
and, interestingly, inhibition of BM-degrading MMPs at this
stage leads to significant acceleration of renal disease.
Collectively, these results suggest that, before the onset of
proteinuria, MMPs are responsible for disease progression,
but after induction of proteinuria and the emergence of
fibrosis, MMPs protect against rapid acceleration of disease.
Tubulointerstitial fibrosis is considered the most common
destructive pathway associated with chronic nephropathies,
including Alport syndrome [9,46]. Renal fibrosis is charac-
terized by a remodeling of the interstitial ECM, resulting in
an excessive deposition of ECM (mainly collagens type I, type
III, and type IV), which culminates in significant deterioration
of renal excretory function [9,47]. The notion that enhanced
degradation of ECM is essential for preventing the accumu-
lation of ECM during fibrosis is not new, and many
investigators have reported on this concept [46]. In such
studies, MMPs are generally considered to be reno-protective,
owing to their potential to cleave interstitial ECM constitu-
ents and reduce scarring [47]. Decreased expression of MMP-
2 and MMP-9, associated with increased expression of their
inhibitors—TIMP-1, TIMP-2, and TIMP-3—was demonstrated
in various independent animal models of renal fibrosis and in
human biopsies [47–50]. Several studies using animal models
of fibrosis demonstrated that a pharmacologic increase of
MMPs can inhibit the deposition of ECM within the
interstitium [51–53]. These observations are consistent with
our findings in the context of renal fibrosis. We propose a
new model for the role of MMPs in the progression of renal
disease associated with Alport syndrome. Before the onset of
proteinuria and significant GBM damage, enhanced MMP
activity is responsible for disease induction owing to the
capacity of MMPs to degrade Alport GBM more rapidly. After
the onset of proteinuria, however, the MMPs are beneficial as
they are responsible for removal of ECM scarring associated
with fibrosis.
Finally, our results offer the possibility of using MMP-
inhibitors as preventive drugs for patients with Alport
syndrome with an established mutation/deletion identifica-
tion and correlative family history. In this regard, MMP-
inhibitors are currently in late-stage clinical trials for many
other indications, and hence are suitable for potential testing
in this setting. However, we also provide evidence that
interference with the MMP system in the context of a chronic
kidney disease can be a double-edged sword that needs to be
approached with great care. Up-regulation of MMPs to
inhibit, or even reverse, the progression of fibrosis has been
proposed as a potential therapeutic approach. Our findings
now demonstrate that MMPs can be equally involved in the
initiation of disease. Collectively, our findings suggest that,
while the inhibition of MMPs before the onset of kidney
disease in patients with Alport syndrome could be beneficial,
this inhibition would have an opposite effect once the disease
process is initiated.
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Patient Summary
Background. Alport syndrome is an inherited disorder in which affected
patients get progressive renal disease associated with nerve deafness
and, occasionally, eye problems. The disease is caused by mutations in
the genes that make up one type of collagen—type IV. This substance is
an essential part of the structure of several organs in the body, including
the glomerular basement membrane which lines the part of the kidney
involved in filtering toxins from the blood into the urine. The
abnormalities in the collagen cause the glomerular basement membrane
to split, thin, and thicken irregularly. These changes lead to blood and
protein appearing in the urine and, eventually, to renal failure.
Why Was This Study Done? Previous work has suggested that the
glomerular basement membrane in patients with Alport syndrome is
unusually susceptible to being damaged by certain enzymes The
researchers wanted to investigate this idea further in a mouse that has
a disease very similar to that of humans, and also in samples taken from
kidneys of people with Alport syndrome.
What Did the Researchers Do and Find? They found that the
glomerular basement membrane in people with Alport syndrome was
very susceptible to being broken down by three different enzymes,
known as matrix metalloproteinases (MMPs) If the mice with disease
similar to Alport syndrome were treated before the onset of kidney
disease, with drugs that prevented these enzymes from working, they
had a less rapid onset of kidney disease. However, giving the drugs after
the kidney disease had begun, led to the disease becoming worse in the
long run, and in the early death of the mice.
What Do These Findings Mean? This study in mice and human kidney
samples shows that MMPs are important at two stages of the kidney
disease of patients with Alport disease. If MMPs are inhibited early on, it
might be possible to slow the progression of the disease. However, once
the disease is established, inhibiting the MMPs would make things
worse. Much more work will need to be done to see whether there are
drugs that inhibit MMPs that can be given safely to patients and, if so,
when exactly the best time is to give them to humans.
Where Can I Get More Information Online? Here are listed several Web
sites with information on Alport syndrome.
Medline Plus:
http://www.nlm.nih.gov/medlineplus/ency/article/000504.htm
Genetics Home Reference, from the US National Library of Medicine
(particularly on the genetics of Alport syndrome):
http://ghr.nlm.nih.gov/condition¼alportsyndrome
National Kidney Foundation:
http://www.kidney.org/kidneydisease
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